NCT04094948

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease Stably Treated With Enzyme Replacement Therapy

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goals of this study are to determine safety and efficacy with regard to motor function of oral clenbuterol in combination with ERT in subjects with LOPD

Conditions

• Pompe Disease (Late-onset)

Interventions

Type	Name	Description
DRUG	Clenbuterol	20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
DRUG	Placebos	dextrose-filled capsules

Timeline

• Start date: 2023-01-01
• Primary completion: 2025-06-30
• Completion: 2025-12-30
• First posted: 2019-09-19
• Last updated: 2022-08-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study